Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 2439Neoplasms 1845Carcinoma, Non-Small-Cell Lung 1615Prostatic Neoplasms 1315Colorectal Neoplasms 1149Lung Neoplasms 993Neoplasm Metastasis 838Multiple Myeloma 802Leukemia, Myeloid, Acute 778Ovarian Neoplasms 686Pancreatic Neoplasms 673Melanoma 669Squamous Cell Carcinoma of Head and Neck 592Carcinoma, Hepatocellular 571Recurrence 570Brain Neoplasms 531Glioblastoma 521Stomach Neoplasms 506Head and Neck Neoplasms 504Triple Negative Breast Neoplasms 474Lymphoma 463Uterine Cervical Neoplasms 457Carcinoma, Renal Cell 430Precursor Cell Lymphoblastic Leukemia-Lymphoma 421Lymphoma, Non-Hodgkin 392Endometrial Neoplasms 386Sarcoma 372Lymphoma, Follicular 358Urinary Bladder Neoplasms 356Lymphoma, Large B-Cell, Diffuse 356

Interventions

trastuzumab deruxtecan 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Unresectable Locally Recurrent Breast Cancer × 1 year × Clear all
NCT07497386 2026-05-11

A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent/Metastatic Breast Cancer

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Recruiting
150 enrolled
Breast

Unresectable Locally Recurrent Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡